Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database
Sukhmani K. Padda(Stanford University), Sunil Badve(Emory University), Bryan M. Burt(Baylor College of Medicine), Heather A. Wakelee(Palo Alto Institute), James Huang(National University Health System), Yue Shang(Dalian Medical University), Alberto Antonicelli(Yale University), Jonathan W. Riess(University of California Davis Medical Center), Joseph B. Shrager(Stanford Medicine), Robert J. Korst(Bristol-Myers Squibb (Germany)), Xiaopan Yao(Dana-Farber Cancer Institute), Frank C. Detterbeck(Yale University)
Unknown
January 1, 2017
Cited by 4
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Methods for Staging Non-small Cell Lung Cancer
|CHEST Journal|2013|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k